# INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Source: https://onco.cc/trials/nct07429266/  
OnCo record `nct07429266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sapablursen in myeloproliferative neoplasms, run by Ono Pharmaceutical Co., Ltd., now recruiting.

## Summary

INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) is a phase 3 interventional study registered as NCT07429266 by Ono Pharmaceutical Co., Ltd., with 250 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-09. Interventions recorded: Sapablursen and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07429266
- Phase: 3
- Setting: A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
- Sponsor: Ono Pharmaceutical Co., Ltd.
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT07429266: https://clinicaltrials.gov/study/NCT07429266

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)

---
JSON: https://onco.cc/api/v1/entities/nct07429266.json